A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Description
This is a single-stage exploratory, Phase 2, multicenter, parallel cohort, open label study designed to evaluate efficacy and safety of VS-6766 + defactinib.
Enrolled study patients will receive the study drugs (VS-6766 and defactinib) to take orally based on the study procedures. Patients will follow the study procedures and attend all the study visits where various procedures including physical examinations, vitals, assessing the size of the patient’s tumor, and examination of urine and blood may take place. Additional visits may be done to assess any other side effects a patient’s experiences.
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites